Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

CAR T-cell Therapy

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

Full ownership lets Kite move faster on anito‑cel’s development.

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel